

Synthesis and Anti-HIV Activity of 4'-Substituted 4'-Thiothymidines: A New Entry Based on Nucleophilic Substitution of the 4'-Acetoxy Group

Kazuhiro Haraguchi,^{*,†} Hisashi Shimada,[†] Hiromichi Tanaka,[†] Takayuki Hamasaki,[‡] Masanori Baba,[‡] Elizabeth A. Gullen,[§] Ginger E. Dutschman,[§] and Yung-Chi Cheng[§]

School of Pharmaceutical Sciences, Showa University, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8555, Japan, Division of Antiviral Chemotherapy, Center for Chronic Viral Diseases, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima 890-8544, Japan, and Department of Pharmacology, School of Medicine, Yale University, New Haven, Connecticut 06520

Received July 9, 2007

Diacetoxylation of 1-(2,5-dideoxy- β -L-glycero-pent-4-eno-4-thiofuranosyl)thymine (**13**) with Pb(OAc)₄ allowed introduction of an acetoxy leaving group to the 4'-position. Nucleophilic substitution of the resulting 4'-acetoxy derivative (**14**) with silicon reagents enabled us to prepare the 4'-phenylthio (**17a**), 4'-azido (**18a**), 4'-methoxy (**20a**), and 4'-allyl (**21a**) analogues of 4'-thiothymidine. 4'-Cyano (**25a**) and 4'-ethynyl (**31**) nucleosides were also synthesized from 3',5'-bis-*O*-TBDMS derivative (**24**). Among novel 4'-substituted 4'-thiothymidines, the 4'-azido (**33**), 4'-cyano (**36**), and 4'-ethynyl (**37**) derivatives were found to show potent inhibitory activity against HIV-1 and HIV-2. It is noteworthy that **36** and **37** were also inhibitory against replication of HIV variant resistant to 3TC (HIV-1_{M184V}), being as potent as against HIV-1_{IIB}.

Introduction

Nucleoside analogues are recognized as an important class of biologically active compounds, especially as antiviral and antitumor agents.¹ Among the sugar-modified nucleosides, 4'-thionucleosides, in which the oxygen atom in the furanose ring is replaced with sulfur atom, have attracted much attention since the discovery that 4'-thiothymidine (**1**) and 4'-thio-2'-deoxycytidine (**2**) possess potent antiviral and antitumor activities (Figure 1).²

Although many reports have dealt with the synthesis of 4'-thionucleoside analogues, the availability of their 4'-substituted derivatives has been quite limited,^{3–5} 2'-deoxy-4'-methyl-4'-thiopyrimidine nucleosides (**I**) being the sole precedent.⁶ In this instance, Vorbrüggen-type glycosidation was applied to the reaction between a 2-deoxy-4-methyl-4-thiofuranosyl derivative and a pyrimidine base, but the undesired α -anomer was also formed.

Recently, it has been reported that 4'-substituted nucleoside such as the 4'-azido (**3**), 4'-methoxy (**4**), 4'-cyano (**5**), and 4'-ethynyl (**6**) analogues of thymidine exhibit potent anti-HIV activity.⁷ These findings motivated us to synthesize their 4'-thio counterparts. We describe here a novel method for the synthesis of 4'-thiothymidines having a variety of 4'-substituents and their inhibitory activity against HIV.

The present method consists of the following two reactions shown in Scheme 1: (1) Pb(OAc)₄-mediated vicinal diacetoxylation of a 4',5'-unsaturated 4'-thiothymidine derivative **II** and (2) nucleophilic substitution of the resulting 4'-acetoxy analogue **III** with silicon reagents to furnish the target molecule **IV**.

Results and Discussion

Preparation of 4',5'-Unsaturated 4'-Thiothymidine (13), the Substrate for Vicinal Diacetoxylation. Compound **13**, 1-(2,5-dideoxy- β -L-glycero-pent-4-eno-4-thiofuranosyl)thym-




Figure 1. 4'-Thionucleosides **1**, **2**, **I**, and 4'-substituted thymidines **3–6**.



ine, was prepared from the TIPDS (1,1,3,3-tetraisopropylidioxane-1,3-diyl)-protected 4-thiofuranoid glycol (**7**) on the basis of electrophilic glycosidation. We have already reported that PhSeCl-mediated glycosidation between **7** and silylated uracil gave both the β - and α -anomers in a ratio of $\beta/\alpha = 18/1$.⁸ When the present reaction of **7** with silylated thymine was carried out using *N*-iodosuccinimide (NIS) as an electrophile, the β -anomer (**8**) was obtained exclusively in 75% yield (Scheme 2). Subsequent radical reduction of **8** with Bu₃SnH/Et₃B/O₂ gave the 4'-thiothymidine derivative (**9**) in 98% yield. Compound **9** was desilylated with Bu₄NF in the presence of Ac₂O to give the 3',5'-di-*O*-acetyl derivative (**10**, 93%). Deacetylation of **10** followed by iodination with I₂/PPh₃ gave 5'-deoxy-5'-iodo-4'-thiothymidine (**11**, 81%). Attempted elimination of HI from **11** by treatment with NaOMe/MeOH resulted in an intractable mixture of products. Therefore, **11** was converted to its 3'-acetate, and the elimination was effected by reacting it with DBN in CH₃CN at room temperature. This gave the 4',5'-

* Corresponding author. Tel: 81-3-3784-8187. Fax: 81-3-3784-8252. E-mail: harakazu@pharm.showa-u.ac.jp.

[†] Showa University.



[‡] Kagoshima University.

[§] Yale University.

Scheme 1. Synthetic Scheme for 4'-Substituted 4'-Thiothymidines**Scheme 2.** Synthesis of 4',5'-Unsaturated 4'-Thiothymidines **12** and **13**

unsaturated derivative **12** in 83% yield. The corresponding 3'-*O*-TBDMS derivative **13** was also prepared in 72% yield from **12**.

Vicinal Diacetoxylation of the 4',5'-Unsaturated Derivatives (12 and 13). Vicinal diacetoxylation of **12** was first examined by reaction with Pb(OAc)₄ (3 equiv) in benzene at room temperature.⁹ However, even after 24 h, most of **12** remained intact. Since the initial step of the diacetoxylation of olefins is considered to be electrophilic in nature, it is conceivable that the presence of an electronegative acetoxy group at the 3'-position of **12** decreases its reactivity toward Pb(OAc)₄.¹⁰ In fact, **13** having a silyloxy group at the 3'-position showed a much higher reactivity. Thus, when the reaction with Pb(OAc)₄ (3 equiv) was carried out under conditions similar to those discussed above, the complete disappearance of **13** was observed after 10 h at room temperature. Three products were obtained from this reaction (Scheme 3). The major product was the 4'-acetoxy-4'-thionucleoside **14** (42%) with the α-L-configuration as evidenced by HMBC correlation (H-5'/5'-OCOMe) and NOE

Scheme 3. Pb(OAc)₄-Mediated Diacetoxylation of **13****Scheme 4.** Mechanism of Diacetoxylation of **13**

experiment (H-6/4'-OCOCH₃: 0.3%). The other two products were the ring-expanded compounds **15** (34%) and **16** (15%), their thiopyranosyl structures being evident from the observed HMBC correlations between H-5' and C-1'.¹¹ A plausible reaction mechanism for the formation of these products is depicted in Scheme 4.


Electrophilic addition of the cationic species (AcO)₃Pb⁺ to the enol thioether structure of **13** leads to the thiocarbenium intermediate **V**, which would prefer the depicted 5'-conformation due to the presence of the 3'-silyloxy group. There could be two possible origins for an acetoxy group to be introduced to the 4'-position: a ligand of the 5'-Pb substituent and the counteranion. By considering the advantage of intramolecular reaction as well as the fact that **14** was formed exclusively, we assume ligand transfer from the 5'-Pb substituent would be a likely pathway.

Upon departure of Pb(OAc)₂ from the resulting intermediate **VI**, there are two competing pathways depending upon the nucleophile. The attack of acetate anion (path a) forms **14**, while that of the sulfur atom (path b) leads to the formation of bicyclo[3.1.0]sulfonium intermediate **VII** and then to the thiopyranosyl carbenium ion **VIII**. Finally, nucleophilic attack of acetate anion would take place either at the 4'-position of **VIII** leading to **15** (path c) or at the carbonyl carbon of the 4'-acetoxy group forming **16** (path d).

Table 1. Reaction of **13** with Pb(OAc)₄^a

entry	solvent	additive (equiv)	yield (%)			
			14 ^b	15 ^c	16 ^c	13 ^b
1	benzene	—	42	34	15	0
2	THF	—	33	5	10	37
3	CH ₂ Cl ₂	—	trace	19	58	0
4	benzene	Na ₂ CO ₃ (2.3)	56	28	14	0


^a All reactions were carried out with Pb(OAc)₄ (3 equiv for entries 1–3 or 2.3 equiv for entry 4) at rt under Ar atmosphere overnight. ^b Isolated yield. ^c The yields of **15** and **16** were calculated by comparison of integration of H-1' in ¹H NMR spectroscopy.

Scheme 5. 4'-Substituted 4'-Thiothymidines **17–21**

In Table 1 are shown several attempts to improve the yield of **14** with the aforementioned result being listed in entry 1. When THF was used as a solvent, a considerable amount of **13** was recovered (entry 2). Use of CH₂Cl₂ encouraged the ring expansion pathway, and **14** was formed in a trace amount (entry 3). A slight increase in the yield of **14** was observed upon carrying out the reaction in benzene in the presence of Na₂CO₃ as shown in entry 4.

Synthesis of 4'-Substituted 4'-Thiothymidines by Displacement of the 4'-Acetoxy Leaving Group. Displacement of the 4'-acetoxy group of **14** was carried out by using silicon reagents in combination with SnCl₄ in CH₂Cl₂ (Scheme 5). The reaction with Me₃SiSPh went to completion after 6 h at –30 °C to give the 4'-phenylthio-β-D-isomer (**17a**) in 74% yield as well as its 4'-epimer (**17b**, 12%). The stereochemistry of these products was assigned on the basis of NOE experiments: **17a**, H-3'/H-5'a (2.7%); Hβ-2'/H-5'b (1.4%); **17b**, H-6/SPh (2.1%).¹² The predominant formation of the 4'-substituted β-D-isomer over its α-L-counterpart was also seen in the reaction with Me₃SiN₃ (**18a**, 69%; **18b**, 30%) and with Me₃SiCH₂CH=CH₂ (**21a/21b** = 10/1, combined yield 53%). In contrast to the above stereochemical trend, the reaction of **14** with Me₃SiOMe/SnCl₄ resulted in the sole formation of the α-L-isomer (**19b**, 58%). The β-D-isomer (**19a**) was formed, as an inseparable mixture with **19b**, when BF₃·OEt₂ was employed as a Lewis acid. Treatment of this mixture with NH₃/MeOH allowed isolation of each isomer, but the α-L-isomer appeared to be the major product (**20a**, 23%; **20b**, 44%).

In the case of the reaction between **14** and Me₃SiCN/SnCl₄, the spiro nucleosides were formed [**22a** (less polar product)/**22b** (more polar product) = 3/10, combined yield 92%], apparently as a result of nucleophilic attack of the carbonyl oxygen of the 5'-O-acetyl group at the 4'-position (Scheme 6). The fact that **22a** and **22b** have the same 4'-configuration supports conformational preference of the 5'-O-acetyl group of the thiocarbenium intermediate as depicted as **IX**, which is reminiscent of **V** in Scheme 4. The observed formation of **22** from **14** led us to prepare a 3',5'-bis-O-silyl-protected substrate


Scheme 6. Reaction of **14** with Me₃SiCN

to introduce a cyano group to the 4'-position. The 4'-phenylthio derivative (**17**, a mixture of two 4'-epimers) prepared above was converted to the 4'-acetoxy-3',5'-bis-O-TBDMS derivative (**24**) over three steps: deacetylation followed by silylation to give **23** (93%), and acetylation of **23** with Hg(OAc)₂/AcOH to yield **24** (98%, **24a/24b** = 4.2/1).

When **24** was reacted with Me₃SiCN/SnCl₄ in CH₂Cl₂ at –30 °C, the desired 4'-cyano derivative **25** was obtained as a mixture of two 4'-epimers albeit in a low yield (**25a/25b** = 4.5/1, combined yield 29%) (Figure 2). In this reaction, two byproduct were obtained: the 4'-isonitrile (**26b**, 11%) with α-L-configuration and the elimination product **27** (27%). In terms of stereoselectivity, use of BF₃·OEt₂ instead of SnCl₄ appeared to be effective, but the yield of **25** remained much the same (**25a/25b** = 20/1, combined yield 37%). Two 4'-isonitriles were also formed in this reaction (**26a**, 23%; **26b**, 9%).¹³ The resulting product **25** was further converted to its 3',5'-di-O-acetyl derivative which could be separated into the α-cyano (**28a**) and β-cyano nucleoside (**28b**).

An attempted introduction of an ethynyl group by reacting **24** with Me₃SiC≡CAI(Cl)Et according to our recently published method⁹ was unsuccessful, forming a complex mixture of products. Therefore, the crude 4'-cyano derivative (**25a**) containing **25b** and **26b** was transformed to the 4'-formyl derivative (**29**) by reacting with Dibal-H followed by acid hydrolysis (Figure 3). Conversion of the 4'-formyl group of **29** to an ethynyl group was carried out by reacting with MeC(O)C(N₂)P(OMe)₂/K₂CO₃ in MeOH.¹⁴ The resulting product **30** was further converted to its 3',5'-di-O-acetyl derivative (**31**) to provide an analytically pure sample (30% yield from **29**).

anti-HIV and anti-HBV Activity of 4'-Substituted 4'-Thiothymidines (32–37). The 4'-substituted derivatives thus prepared were deprotected to yield the corresponding free 4'-

**Figure 2.** Compounds **23–28**.




Figure 3. Compounds 29–31.




Figure 4. 4'-Substituted 4'-thiothymidines 32–37.

Table 2. Inhibitory Effects of 4'-Substituted 4'-Thiothymidines (32–37) on HIV-1 and HIV-2 Replication in Cell Culture

compd	4'-substituent	HIV-1		HIV-2 (EHO)	
		EC ₅₀ (μM) ^a	CC ₅₀ (μM) ^b	EC ₅₀ (μM) ^c	CC ₅₀ (μM) ^d
32	SPh	>100	>100	>100	>100
33	N ₃	0.02	40	0.024	>10
34	OMe	>4.0	>100	1.2	>100
35	CH ₂ CH=CH ₂	>100	>100	>100	>100
36	C≡N	0.037	>100	0.023	>10
37	C≡CH	0.31	>100	0.13	>10

^a Inhibitory concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1_{IIIb}. ^b Cytotoxic concentration required to reduce the viability of mock-infected MT-4 cells by 50%. ^c Inhibitory concentration required to achieve 50% protection of M8166 cells against the cytopathic effect of HIV-2. ^d Cytotoxic concentration required to reduce the viability of mock-infected M8166 cells by 50%.

thiothymidines (32–37) (Figure 4). Table 2 summarizes the anti-HIV-1 activity, HIV-2 activity, and cytotoxicity of these compounds. Except for the 4'-phenylthio (32) and 4'-allyl (35) analogues, the compounds synthesized in this study showed inhibitory activity against HIV-1. Especially, the 4'-azido (33), 4'-cyano (36), and 4'-ethynyl (37) analogues exhibited potent anti-HIV activity, with EC₅₀'s of 0.02, 0.037, and 0.31 μM, respectively, although 33 showed a significant cytotoxicity to MT-4 cells. Compounds 33, 36, and 37 also showed inhibitory activity against HIV-2 as shown in Table 2. With regard to 36 and 37, the activity against HIV-1 variant resistant to 3TC (HIV-1_{M184V}) was also tested. It was found that these compounds suppressed replication of HIV-1_{M184V} with an almost equal potency to HIV-1_{IIIb} (data not shown). These compounds did not show any anti-HBV activity up to 10 μM.¹⁵

Comparison of the selectivity indices (SI) was made between 4'-substituted 4'-thiothymidines (33, 34, 36, and 37) and the corresponding thymidine derivatives (3–6) by employing the reported CC₂₅/EC₅₀ values of 3–5¹ or CC₅₀/EC₅₀ value of 6.¹⁶ In the case of 4'-azido-, 4'-methoxy-, and 4'-ethynyl derivatives, comparable SI values were obtained: 3 (800) and 33 (670); 4 (>24) and 34 (>11); 6 (>120) and 37 (>322). Interestingly, 4'-cyano-4'-thiothymidine 36 was found to possess an SI value of 1586, which is three times better than that of 4'-cyanothymidine (5) (SI 500).

Conclusion

In conclusion, we have developed a novel synthetic approach to 4'-substituted 4'-thiothymidines on the basis of nucleophilic substitution. For the preparation of the substrate 14 having an acetoxy leaving group at the 4'-position, vicinal diacetoxylation

of the 4',5'-unsaturated 4'-thiothymidine 13 was employed. During this diacetoxylation reaction, ring-expansion to the thiopyranosides (15 and 16) was observed. Lewis acid assisted nucleophilic substitution of 14 furnished the desired compounds such as the 4'-phenylthio (17a), 4'-azido (18a), 4'-methoxy (20a), 4'-allyl (21a), and 4'-cyano (28a) analogues of 4'-thiothymidine. The 4'-ethynyl (31) analogue was also synthesized. Among the six deprotected 4'-substituted 4'-thiothymidines (32–37), the 4'-azido (33), 4'-cyano (36), and 4'-ethynyl (37) analogues showed inhibitory activity against HIV-1 as well as HIV-2. In particular, the 4'-cyano derivative 36 exhibited a potent anti-HIV-1 activity with EC₅₀ 0.037 μM and did not show any cytotoxicity to MT-4 cells up to 100 μM. It is noteworthy that 4'-cyano (36) and 4'-ethynyl (37) analogues of 4'-thiothymidine were also inhibitory to replication of HIV-1 variant resistant to 3TC (HIV-1_{M184V}). By comparison with the reported SI value 4'-cyanothymidine, it was found that the 4'-thio counterpart (36) has a 3-fold better value. These facts suggest that replacement of the furanose oxygen with sulfur atom is a promising approach for development of new nucleoside antiviral agents. As have already been published from our laboratory,^{3b,4,8} the present glycosidation method, electrophilic addition of nucleobases to 4-thiofuranoid glycols, is applicable to the preparation of cytosine and adenine 4'-thionucleosides. We are currently working along this line.

Experimental Section

Chemistry. Melting points are uncorrected. ¹H and ¹³C NMR spectra were recorded either at 400 MHz or at 500 MHz. Chemical shifts are reported relative to Me₄Si. Mass spectra (MS) were taken in FAB mode with *m*-nitrobenzyl alcohol as a matrix. Column chromatography was carried out on silica gel. Thin-layer chromatography (TLC) was performed on silica gel. When necessary, analytical samples were purified by high-performance liquid chromatography (HPLC). THF was distilled from benzophenone ketyl.

Diacetoxylation of 13 with Pb(OAc)₄: 1-[4-O-Acetoxy-5-O-acetyl-3-O-(tert-butyltrimethylsilyl)-2-deoxy-α-L-threo-4-thio-pentofuranosyl]thymine (14), 5,5-Bis-acetoxy-(4S)-O-(tert-butyltrimethylsilyl)-(2R)-(thymine-1-yl)thiane (15), and (4S)-O-(tert-butyltrimethylsilyl)-(2R)-(thymine-1-yl)thian-5-one (16). To a benzene (50 mL) solution of 13 (1.45 g, 4.09 mmol) were added Na₂CO₃ (996.3 mg, 9.4 mmol) and Pb(OAc)₄ (4.2 g, 9.4 mmol) at 0 °C under Ar atmosphere, and the mixture was stirred at rt overnight, quenched with saturated aq NaHCO₃, and filtered through a Celite pad. The filtrate was partitioned between CHCl₃/saturated aq NaHCO₃. Column chromatography (hexane/AcOEt = 2/1–1/1) of the organic layer gave 14 (1.08 g, 56%, foam) and a mixture of 15 and 16 (749.8 mg) [15: 530.8 mg (28%), 16: 219 mg (14%), calculated by comparison of integration of H-1']. Compounds 15 (foam, t_R 20.0 min) and 16 (solid, t_R 17.7 min) were separated by HPLC (hexane/EtOAc = 1/2).

Physical data of 14: UV (MeOH) λ_{max} 269 nm (ε 10800), λ_{min} 236 nm (ε 2700). ¹H NMR (CDCl₃) δ 0.12 and 0.16 (6H, each as s), 0.93 (9H, s), 1.93 (3H, d, *J* = 1.2 Hz), 2.07 (3H, s), 2.13 (3H, s), 2.23 (1H, ddd, *J* = 10.0, 12.4, 3.2 Hz), 2.45 (1H, dd, *J* = 6.0, 12.4 Hz), 4.41 (1H, d, *J* = 12.0 Hz), 5.12 (1H, d, *J* = 12.0 Hz), 4.54 (1H, br), 6.62 (1H, dd, *J* = 10.0, 6.0 Hz), 7.27 (1H, d, *J* = 1.2 Hz), 8.95 (1H, br); NOE experiment H-6/CH₃CO-4' (0.3%); HMBC H-5'/CH₃CO-5'; ¹³C NMR (CDCl₃) δ -5.3, -4.7, 12.7, 17.7, 20.6, 21.6, 25.4, 41.7, 61.4, 61.5, 76.5, 100.3, 111.9, 135.6, 150.5, 163.6, 168.7, 169.7; FAB-MS (*m/z*) 435 and 473 (M⁺ + H). Anal. Calcd for C₂₀H₃₂N₂O₇SSi: C, 50.83; H, 6.82; N, 5.93. Found: C, 50.93; H, 6.86; N, 5.87.

Physical data of 15: UV (MeOH) λ_{max} 269 nm (ε 11100), λ_{min} 235 nm (ε 2300); ¹H NMR (CDCl₃) δ 0.06 and 0.11 (6H, each as s), 0.91 (9H, s), 1.95 (3H, d, *J* = 1.2 Hz), 2.06 (3H, s), 2.11 (1H, ddd, *J* = 2.9, 13.4, 4.6 Hz), 2.20 (3H, s), 2.47 (1H, ddd, *J* = 12.2, 13.4, 2.0 Hz), 3.61 (2H, s), 4.91 (1H, d, *J* = 3.2 Hz), 6.21 (1H, dd,

1-[4-Azido-2-deoxy- β -D-erythro-4-thiopentofuranosyl]thymine (33). To a THF (3 mL) solution of **18a** (60.2 mg, 0.13 mmol) was added Bu₄NF·3H₂O (52.3 mg, 0.20 mmol) at 0 °C, and the mixture was stirred for 1 h. Silica gel column chromatography (3% MeOH in CH₂Cl₂) of the reaction mixture gave 1-[5-*O*-acetyl-4-azido-2-deoxy- β -D-erythro-4-thiopentofuranosyl]thymine. The product was treated with methanolic ammonia (6 mL) at rt for 6 h. The reaction mixture was evaporated to dryness. Silica gel column chromatography (3% MeOH in CH₂Cl₂) of the residue gave **33** (30.9 mg, 79%) as syrup, which was triturated from Et₂O: IR (KBr) 2117 cm⁻¹ (N₃); mp 100–102 °C; UV (MeOH) λ_{\max} 270 nm (ϵ 12800), λ_{\min} 237 nm (ϵ 4100); ¹H NMR (CD₃OD) δ 1.91 (3H, d, J = 1.0 Hz), 2.41–2.54 (2H, m), 3.77 (1H, d, J = 11.7 Hz), 3.82 (1H, d, J = 11.7 Hz), 4.48 (1H, dd, J = 5.1, 7.1 Hz), 6.41 (1H, d, J = 6.1), 7.88 (1H, d, J = 1.0 Hz); ¹³C NMR (CD₃OD) δ 13.0, 42.0, 60.4, 67.8, 77.5, 88.1, 112.7, 138.9, 153.0, 166.5; FAB-MS (m/z) 300 (M⁺ + H). Anal. Calcd for C₁₀H₁₃N₅O₄S·¹/₂AcOMe: C, 41.07; H, 4.79; N, 20.82. Found: C, 41.00; H, 4.44; N, 21.22.

1-[2-Deoxy-4-methoxy- β -D-erythro-4-thiopentofuranosyl]thymine (34). To a THF (3.0 mL) solution of **20a** (49.5 mg, 0.12 mmol) was added Bu₄NF·3H₂O (47.1 mg, 0.18 mmol) at 0 °C, and the mixture was stirred for 1 h. Silica gel column chromatography (3% MeOH in CH₂Cl₂) of the reaction mixture gave **34** (30.7 mg, 89%), which was triturated from Et₂O: mp 85–87 °C; UV (MeOH) λ_{\max} 271 nm (ϵ 10200), λ_{\min} 238 nm (ϵ 2480); ¹H NMR (CD₃OD) δ 1.90 (3H, d, J = 1.0 Hz), 2.33 (1H, ddd, J = 3.4, 5.6, 10.7 Hz), 2.58 (1H, ddd, J = 7.3, 10.0, 10.7 Hz), 3.46 (3H, s), 3.84 (1H, d, J = 10.5 Hz), 3.94 (1H, d, J = 10.5 Hz), 4.51 (1H, dd, J = 5.6, 10.0 Hz), 6.15 (1H, dd, J = 3.4, 7.3 Hz), 8.00 (1H, d, J = 1.0 Hz); ¹³C NMR (CD₃OD) δ 12.6, 42.0, 53.1, 58.8, 63.0, 75.1, 101.9, 111.7, 138.9, 152.6, 166.2; FAB-MS (m/z) 289 (M⁺ + H). Anal. Calcd for C₁₁H₁₆N₂O₅S: C, 45.82; H, 5.59; N, 9.72. Found: C, 45.95; H, 5.9; N, 9.41.

1-[4-Allyl-2-deoxy- β -D-erythro-4-thiopentofuranosyl]thymine (35). To a THF (3.5 mL) solution of **21a** (93.4 mg, 0.21 mmol) was added Bu₄NF·3H₂O (100.2 mg, 0.38 mmol) at 0 °C, and the mixture was stirred for 2 h. Silica gel column chromatography (2% MeOH in CH₂Cl₂) of the reaction mixture gave 5'-*O*-acetyl derivative. The acetate was treated with methanolic ammonia (2.5 mL) at rt for 7 h. The reaction mixture was evaporated to dryness. Silica gel column chromatography of the crude product gave **35** (38.8 mg, 46%) as syrup, which was triturated from Et₂O: mp 86–88 °C; UV (MeOH) λ_{\max} 272 nm (ϵ 9800), λ_{\min} 237 nm (ϵ 2600); ¹H NMR (CD₃OD) δ 1.90 (3H, d, J = 1.0 Hz), 2.40–2.43 (2H, m), 2.54–2.56 (2H, m), 3.68 (2H, s), 4.38 (1H, t, J = 4.4 Hz), 5.09 (1H, dd, J = 2.4, 10.0 Hz), 5.15 (1H, dd, J = 2.4, 16.8 Hz), 5.81–5.91 (1H, m), 6.36 (1H, t, J = 7.2 Hz), 8.10 (1H, d, J = 1.2 Hz); ¹³C NMR (CD₃OD) δ 13.0, 39.3, 44.1, 61.5, 67.3, 68.1, 76.4, 112.2, 119.3, 136.5, 139.7, 153.1, 166.7; FAB-MS (m/z) 299 (M⁺ + H). Anal. Calcd for C₁₃H₁₉N₂O₄S: C, 52.33; H, 6.08; N, 9.39. Found: C, 52.10; H, 5.98; N, 9.05.

1-[4-Cyano-2-deoxy- β -D-erythro-4-thiopentofuranosyl]thymine (36). Compound **28a** was treated with methanolic ammonia (8 mL) at rt for 9 h. The reaction mixture was evaporated to dryness. Silica gel column chromatography (3% MeOH in CH₂Cl₂) of the residue gave **36** (21.5 mg, 77%) as syrup, which was triturated from Et₂O: IR (KBr) 2223 cm⁻¹ (C≡N); mp 234–237 (dec) °C; UV (MeOH) λ_{\max} 270 nm (ϵ 10500), λ_{\min} 236 nm (ϵ 2500); ¹H NMR (CD₃OD) δ 1.90 (3H, d, J = 1.2 Hz), 2.46–2.58 (2H, m), 3.91 (1H, d, J = 11.7 Hz), 3.95 (1H, d, J = 11.7 Hz), 4.59 (1H, dd, J = 4.9, 6.6 Hz), 6.43 (1H, t, J = 6.6 Hz), 7.82 (1H, d, J = 1.2 Hz); ¹³C NMR (CD₃OD) δ 12.5, 41.9, 61.16, 61.23, 66.0, 75.0, 112.3, 119.8, 138.3, 152.4, 166.0; FAB-MS (m/z) 284 (M⁺ + H). Anal. Calcd for C₁₁H₁₃N₃O₄S: C, 46.63; H, 4.63; N, 14.83. Found: C, 46.70; H, 4.60; N, 14.47.

1-[2-Deoxy-4-ethynyl- β -D-erythro-4-thiopentofuranosyl]thymine (37). Compound **31** (25.5 mg, 0.07 mmol) was treated with methanolic ammonia (5 mL) at rt for 5 h. The reaction mixture was evaporated to dryness. Silica gel column chromatography (3% MeOH in CH₂Cl₂) of the residue gave **37** (16.7 mg, 84%) as syrup, which was triturated from Et₂O: IR (KBr) 2103 cm⁻¹ (C≡CH);

mp 229–231 °C; UV (MeOH) λ_{\max} 270 nm (ϵ 10100), λ_{\min} 237 nm (ϵ 2500); ¹H NMR (CD₃OD) δ 1.90 (3H, d, J = 1.2 Hz), 2.40 (1H, ddd, J = 4.6, 5.1, 13.4 Hz), 2.58 (1H, ddd, J = 6.8, 7.9, 13.4 Hz), 2.95 (1H, s), 3.79 (1H, d, J = 11.7 Hz), 3.87 (1H, d, J = 11.7 Hz), 4.41 (1H, dd, J = 4.6, 7.9 Hz), 6.31 (1H, dd, J = 5.1, 6.8 Hz), 8.11 (1H, t, J = 1.2 Hz); ¹³C NMR (CD₃OD) δ 12.5, 42.7, 60.3, 61.5, 66.8, 75.1, 77.2, 82.8, 111.6, 139.0, 152.6, 166.2; FAB-MS (m/z) 283 (M⁺ + H) and 267 (M⁺ - OH). Anal. Calcd for C₁₂H₁₄N₂O₄S₂·¹/₄H₂O: C, 50.25; H, 5.10; N, 9.77. Found: C, 50.21; H, 4.96; N, 9.90.

Anti-HIV Assay. MT-4 cells¹⁷ were maintained in RPMI 1640 medium supplemented with 10% heat-inactivated fetal bovine serum (FBS), 100U/mL of penicillin G, and 100 mg/mL of streptomycin. The III_B strain of HIV-1 was used throughout the experiment. The virus was propagated and titrated in MT-4 cells. Virus stocks were stored at -80 °C until use.

The anti-HIV-1 activity of the test compounds was determined by the inhibition of either virus-induced cytopathogenicity in MT-4 cells.¹⁸ Briefly, MT-4 cells (1 × 10⁵ cells/mL) were infected with HIV-1 at a multiplicity of infection (MOI) of 0.02 and were cultured in the presence of various concentrations of the test compounds. In the case of HIV-2, M8166 cells (1 × 10⁵) were infected at a MOI of 0.1. After a 4-day incubation at 37 °C, the number of viable cells was monitored by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) method.¹⁹ The cytotoxicity of the compounds was evaluated in parallel with their antiviral activity, based on the viability of mock-infected cells, as determined by the MTT method.

Acknowledgment. Financial support from the Japan Society for the Promotion of Science (KAKENHI No. 19590106 to K.H. and No. 17590094 to H.T.), the Research Foundation of Pharmaceutical Sciences (to K.H.), and the Japan Health Sciences Foundation (SA 14804 to H.T.) is gratefully acknowledged. We are also grateful to Ms. K. Shiohara and Y. Odanaka (Center for Instrumental Analysis, Showa University) for technical assistance with NMR, MS, and elemental analyses. Dr. T. Hamasaki is a Research Resident of the Japanese Foundation for AIDS Prevention.

Supporting Information Available: Experimental procedures and full characterization for compounds **8–13**. This material is available free of charge via the Internet at <http://pubs.acs.org>.

References

- (1) For a review, see: *Nucleosides and Nucleotides as Antitumor and Antiviral Agents*; Chu, C. K., Baker, D. C., Eds.; Plenum Press: New York, 1993.
- (2) For a review, see: Yokoyama, M. Synthesis and biological activity of thionucleosides. *Synthesis* **2000**, 1637–1655.
- (3) For examples of 1'-carbon-substituted analogues, see: (a) MacCulloch, A.; Coe, P.; Walker, R. T. Stereoselective synthesis of novel 1'-substituted 2'-deoxy-4'-thionucleosides. *J. Chem. Soc., Perkin Trans.* **1999**, *1*, 335–339. (b) Haraguchi, K.; Takahashi, H.; Tanaka, H. Stereoselective entry to 1'-C-branched 4'-thionucleosides from 4-thiofuranoid glycol: synthesis of 4'-thioangustmycin C. *Tetrahedron Lett.* **2002**, *43*, 5657–5660.
- (4) For an example of 2'- β -carbon-substituted analogues, see: Haraguchi, K.; Shiina, N.; Yoshimura, Y.; Shimada, H.; Hashimoto, K.; Tanaka, H. Novel stereoselective entry to 2'- β -carbon-substituted 2'-deoxy-4'-thionucleosides from 4-thiofuranoid glycols. *Org. Lett.* **2004**, *16*, 2645–2648.
- (5) For an example of 3'-carbon-substituted analogues, see: Branalt, J.; Kvarnstrom, I.; Niklasson, S. C. T.; Classon, B.; Samuelson, B. Synthesis of 2',3'-dideoxy-3'-C-(hydroxymethyl)-4'-thionucleosides as potential inhibitor of HIV. *J. Org. Chem.* **1994**, *59*, 1783–1788.
- (6) Uenishi, J. Acyclic and stereocontrolled synthesis of thiosugars and preparation of pseudonucleoside having the thiosugar moiety. *J. Synth. Org. Chem. Jpn.* **1997**, *55*, 186–195.
- (7) For a review, see: Hayakawa, H.; Kohgo, S.; Kitano, K.; Ashida, N.; Kodama, E.; Mitsuya, H.; Ohru, H. Potential of 4'-C-substituted nucleosides for the treatment of HIV-1. *Antiviral Chem. Chemother.* **2004**, *15*, 169–187.

- (8) Haraguchi, K.; Takahashi, H.; Shiina, N.; Horii, C.; Yoshimura, Y.; Nishikawa, A.; Sasakura, E.; Nakamura, K. T.; Tanaka, H. Stereoselective synthesis of the β -anomer of 4'-thionucleosides based on electrophilic glycosidation to 4-thiofuranoid glycols. *J. Org. Chem.* **2002**, *67*, 5919–5927.
- (9) We have recently reported the synthesis of 4'-benzoyloxythymidine nucleoside by the reaction of 4',5'-unsaturated derivative with $\text{Pb}(\text{OBz})_4$. Haraguchi, K.; Sumino, M.; Tanaka, H. Nucleophilic substitution at the 4'-position of nucleosides: new access to a promising anti-HIV agent 2',3'-dideoxy-3'-deoxy-4'-ethynylthymidine. *J. Org. Chem.* **2006**, *71*, 4433–4438.
- (10) Inamoto, N.; Masuda, S. Revised method for calculation of group electronegativities. *Chem. Lett.* **1982**, 1003–1006.
- (11) For examples of ring-expansion reactions, see: (a) Al-Masoudi, N. A. L.; Al-Soud, Y. A.; Schuppler, T. Thiosugar nucleosides. Effect of sulfur in the synthesis of substituted azido-5-thio-D-gluco- and allopuranosyl-N-nucleosides and new isothionucleoside derivative thereof. *J. Carbohydr. Chem.* **2005**, *24*, 237–250. (b) Al-Masoudi, N. A. L.; Hughes, N. A. Sulfur participation in displacement reactions of sulfonate ester of 5-thio-D-allose, 5-thio-D-altrose, and 5-thio-D-glucose derivatives. *J. Chem. Soc., Perkin Trans. 1* **1987**, 2061–2067.
- (12) Of the two protons at the 5'-position, the one that appears at a higher field is designated as H-5'a, and the other as H-5'b, throughout the text and Experimental Section.
- (13) Synthesis of isonitrile by nucleophilic substitution: Masutani, K.; Minowa, T.; Mukaiyama, T. Selective synthesis of isocyanides from secondary alcohols by a new type of oxidation-reduction condensation. *Chem. Lett.* **2005**, *34*, 1124–1125, and references cited therein.
- (14) Müller, S.; Liepold, B.; Roth, G. J.; Bestmann, H. J. An improved one-pot procedure for the synthesis of alkynes from aldehydes. *Synlett* **1996**, 521–522.
- (15) Method for evaluation of anti-HBV activity: Doong, S. L.; Tsai, C. H.; Schinazi, R. F.; Liotta, D. C.; Cheng, Y. C. Inhibition of the replication of hepatitis B virus *in vitro* by 2', 3'-dideoxy-3'-thiacytidine and related analogues. *Proc. Natl. Acad. Sci. U.S.A.* **1991**, *88*, 8495–8499.
- (16) Sugimoto, I.; Shuto, S.; Mori, S.; Shigeta, S.; Matsuda, A. Synthesis of 4' α -branched thymidines as a new type of antiviral agent. *Bioorg. Med. Chem. Lett.* **1999**, *9*, 385–388.
- (17) Miyoshi, I.; Taguchi, H.; Kubonishi, I.; Yoshimoto, S.; Ohtsuki, Y.; Shiraishi, Y.; Akagi, T. Type C virus-producing cell line derived from adult T cell leukemia. *Gann Monogr. Cancer Res.* **1982**, *28*, 219–228.
- (18) Baba, M.; De Clercq, E.; Tanaka, H.; Ubasawa, M.; Takashima, H.; Sekiya, K.; Nitta, I.; Umezu, K.; Nakashima, H.; Mori, S.; Shigeta, S.; Walker, R. T.; Miyasaka, T. Potent and selective inhibition of human immunodeficiency virus type 1 (HIV-1) by 5-ethyl-6-phenylthiouracil derivatives through their interaction with the HIV-1 reverse transcriptase. *Proc. Natl. Acad. Sci. U.S.A.* **1991**, *88*, 2356–2360.
- (19) Pauwels, R.; Balzarini, J.; Baba, M.; Snoeck, R.; Schols, D.; Herdewijn, P.; Desmyter, J.; De Clercq, E. Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. *J. Virol. Methods* **1988**, *20*, 309–312.

JM070824S